{"id":"pyrimethamine-sulfadiazine-prednisolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Rash / Stevens-Johnson syndrome risk"},{"rate":null,"effect":"Immunosuppression-related infections"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Corticosteroid-related adverse effects (hyperglycemia, osteoporosis)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Pyrimethamine and sulfadiazine work synergistically to inhibit folate metabolism in parasites (particularly Toxoplasma gondii), disrupting nucleotide synthesis and parasite replication. Prednisolone, a corticosteroid, reduces inflammation and modulates immune responses, potentially preventing immune-mediated complications. This combination is typically used in conditions where parasitic infection triggers significant inflammatory pathology.","oneSentence":"This combination uses pyrimethamine and sulfadiazine as antimicrobial agents to treat parasitic or protozoal infections, while prednisolone provides immunosuppression and anti-inflammatory effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:53.195Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Toxoplasmosis with inflammatory complications"},{"name":"Parasitic infections requiring immunosuppressive management"}]},"trialDetails":[{"nctId":"NCT00372294","phase":"PHASE3","title":"To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2005-07","conditions":"Chorioretinitis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"pyrimethamine-sulfadiazine + prednisolone","genericName":"pyrimethamine-sulfadiazine + prednisolone","companyName":"Shahid Beheshti University of Medical Sciences","companyId":"shahid-beheshti-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses pyrimethamine and sulfadiazine as antimicrobial agents to treat parasitic or protozoal infections, while prednisolone provides immunosuppression and anti-inflammatory effects. Used for Toxoplasmosis with inflammatory complications, Parasitic infections requiring immunosuppressive management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}